Loading…
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $321.3B | $3.7B | $1.6B | $3.2B | 103.1% | 9.3% | 3.0% |
| 2024 | $294.0B | $3.4B | $1.5B | $3.0B | 233.6% | 12.1% | -13.5% |
| 2023 | $262.2B | $3.4B | $1.7B | $3.5B | 334.3% | 9.9% | 2.7% |
| 2022 | $238.6B | $3.1B | $1.7B | $2.2B | -803.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 238,587.01 | 262,173.41 | 293,958.60 | 321,332.82 |
| Operating Revenue | - | 238,587.01 | 262,173.41 | 293,958.60 | 321,332.82 |
| Cost Of Revenue | - | 230,290.64 | 253,213.92 | 284,048.57 | 309,854.28 |
| Gross Profit | - | 8,296.37 | 8,959.49 | 9,910.03 | 11,478.54 |
| Operating Expense | - | 5,542.86 | 6,273.89 | 6,753.08 | 7,544.92 |
| Selling General And Administration | - | 4,848.96 | 5,309.98 | 5,661.11 | 6,493.84 |
| Total Expenses | - | 235,833.50 | 259,487.81 | 290,801.65 | 317,399.20 |
| Operating Income | - | 2,753.51 | 2,685.60 | 3,156.95 | 3,933.62 |
| Total Operating Income As Reported | - | 2,366.38 | 2,340.73 | 2,175.25 | 2,628.60 |
| EBITDA | - | 3,103.56 | 3,370.62 | 3,371.50 | 3,746.50 |
| Normalized EBITDA | - | 3,490.70 | 3,715.49 | 4,353.20 | 5,051.53 |
| EBIT | - | 2,393.73 | 2,389.77 | 2,252.66 | 2,678.09 |
| Interest Income | - | 21.31 | 46.72 | 91.69 | 128.21 |
| Interest Expense | - | 210.67 | 228.93 | 248.68 | 419.75 |
| Net Interest Income | - | -210.67 | -228.93 | -156.99 | -291.55 |
| Other Non Operating Income Expenses | - | 27.35 | 49.04 | -14.28 | -78.72 |
| Other Income Expense | - | -359.78 | -295.84 | -995.98 | -1,383.74 |
| Interest Income Non Operating | - | 21.31 | 46.72 | 91.69 | 128.21 |
| Interest Expense Non Operating | - | 210.67 | 228.93 | 248.68 | 419.75 |
| Net Non Operating Interest Income Expense | - | -210.67 | -228.93 | -156.99 | -291.55 |
| Pretax Income | - | 2,183.06 | 2,160.84 | 2,003.98 | 2,258.34 |
| Tax Provision | - | 516.52 | 428.26 | 484.70 | 690.52 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -91.75 | -68.29 | -237.44 | -399.03 |
| Net Income Continuous Operations | - | 1,666.54 | 1,732.58 | 1,519.27 | 1,567.81 |
| Net Income From Continuing And Discontinued Operation | - | 1,698.82 | 1,745.29 | 1,509.12 | 1,554.17 |
| Net Income From Continuing Operation Net Minority Interest | - | 1,698.82 | 1,745.29 | 1,509.12 | 1,554.17 |
| Net Income | - | 1,698.82 | 1,745.29 | 1,509.12 | 1,554.17 |
| Net Income Common Stockholders | - | 1,698.82 | 1,745.29 | 1,509.12 | 1,554.17 |
| Net Income Including Noncontrolling Interests | - | 1,666.54 | 1,732.58 | 1,519.27 | 1,567.81 |
| Normalized Income | - | 1,994.20 | 2,021.88 | 2,253.38 | 2,460.16 |
| Diluted NI Availto Com Stockholders | - | 1,698.82 | 1,745.29 | 1,509.12 | 1,554.17 |
| Basic Average Shares | - | 208.47 | 202.51 | 198.50 | 193.82 |
| Diluted Average Shares | - | 211.21 | 204.59 | 200.28 | 195.21 |
| Reconciled Depreciation | - | 709.84 | 980.85 | 1,118.84 | 1,068.42 |
| Reconciled Cost Of Revenue | - | 230,274.70 | 253,196.97 | 284,021.70 | 309,836.94 |
| Total Unusual Items | - | -387.13 | -344.87 | -981.70 | -1,305.02 |
| Total Unusual Items Excluding Goodwill | - | -387.13 | -344.87 | -981.70 | -1,305.02 |
| Minority Interests | - | 32.28 | 12.72 | -10.15 | -13.64 |
| Special Income Charges | - | -387.13 | -344.87 | -981.70 | -1,305.02 |
| Other Special Charges | - | 123.19 | -24.69 | 227.07 | 60.67 |
| Write Off | 11.32 | 4.95 | 0 | 0 | - |
| Impairment Of Capital Assets | - | 75.94 | 0 | 418 | 723.88 |
| Restructuring And Mergern Acquisition | - | 183.06 | 369.57 | 336.63 | 520.47 |
| Depreciation Amortization Depletion Income Statement | - | 693.90 | 963.90 | 1,091.97 | 1,051.08 |
| Depreciation And Amortization In Income Statement | - | 693.90 | 963.90 | 1,091.97 | 1,051.08 |
| Amortization | - | 307.30 | 553.56 | 663.47 | 556.93 |
| Amortization Of Intangibles Income Statement | - | 307.30 | 553.56 | 663.47 | 556.93 |
| Depreciation Income Statement | - | 386.60 | 410.34 | 428.50 | 494.14 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Cencora, Inc.this co. | COR | $52.6B | 33.84 | 34.88 | 103.1% | 14.92 |
| Regeneron Pharmaceuticals, Inc. | REGN | $65.9B | 14.63 | 2.11 | 14.4% | 11.26 |
| Edwards Lifesciences Corporation | EW | $50.4B | 46.91 | 4.87 | 10.4% | 33.19 |
| Cardinal Health, Inc. | CAH | $47.2B | 30.27 | -16.99 | -56.1% | 16.71 |
| IDEXX Laboratories, Inc. | IDXX | $44.5B | 42.05 |
| - |
| - |
| - |
| - |
| 27.75 |
| 66.0% |
| 30.06 |
| Humana Inc. | HUM | $42.0B | 35.35 | 2.38 | 6.7% | - |
| Becton, Dickinson and Company | BDX | $41.2B | 24.56 | 1.62 | 6.6% | 12.06 |
| Alnylam Pharmaceuticals, Inc. | ALNY | $40.5B | 129.21 | 51.37 | 39.8% | 61.62 |
| Agilent Technologies, Inc. | A | $39.1B | 29.99 | 5.80 | 19.3% | 22.15 |
| Peer Median | - | 32.81 | 3.62 | 12.4% | 22.15 | |